Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hess

Showing results (1111-1120 of 1,218) with videos related to

Pageof 122
Sort By:
Transfusion|March 30, 2010
Evidence-based practice guidelines for plasma transfusionJohn D Roback, Stephen Caldwell, Jeff Carson, et al.
Neuro-Oncology|February 11, 2004
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium studyMichael D Prados, W K Alfred Yung, Howard A Fine, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 2, 2015
Trichodesmium genome maintains abundant, widespread noncoding DNA in situ, despite oligotrophic lifestyleNathan Walworth, Ulrike Pfreundt, William C Nelson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancerRoman Rouzier, Lajos Pusztai, Suzette Delaloge, et al.
Oncotarget|October 15, 2014
Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trialsRabih Said, Yang Ye, Gerald Steven Falchook, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2006
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancerKenneth R Hess, Keith Anderson, W Fraser Symmans, et al.
Journal of Translational Medicine|February 11, 2016
Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cellsTakashi Shingu, Lindsay Holmes, Verlene Henry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2019
Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic CancerSeyed Pairawan, Kenneth R Hess, Filip Janku, et al.
The Oncologist|August 25, 2018
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast CancerReva K Basho, Clinton Yam, Michael Gilcrease, et al.
CA: a Cancer Journal for Clinicians|January 20, 2016
American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicineMichael W Kattan, Kenneth R Hess, Mahul B Amin, et al.
Pageof 122

Showing results (1111-1120 of 1,218) with videos related to

Sort By:
Pageof 122
Transfusion|March 30, 2010
Evidence-based practice guidelines for plasma transfusionJohn D Roback, Stephen Caldwell, Jeff Carson, et al.
Neuro-Oncology|February 11, 2004
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium studyMichael D Prados, W K Alfred Yung, Howard A Fine, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 2, 2015
Trichodesmium genome maintains abundant, widespread noncoding DNA in situ, despite oligotrophic lifestyleNathan Walworth, Ulrike Pfreundt, William C Nelson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancerRoman Rouzier, Lajos Pusztai, Suzette Delaloge, et al.
Oncotarget|October 15, 2014
Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trialsRabih Said, Yang Ye, Gerald Steven Falchook, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2006
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancerKenneth R Hess, Keith Anderson, W Fraser Symmans, et al.
Journal of Translational Medicine|February 11, 2016
Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cellsTakashi Shingu, Lindsay Holmes, Verlene Henry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2019
Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic CancerSeyed Pairawan, Kenneth R Hess, Filip Janku, et al.
The Oncologist|August 25, 2018
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast CancerReva K Basho, Clinton Yam, Michael Gilcrease, et al.
CA: a Cancer Journal for Clinicians|January 20, 2016
American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicineMichael W Kattan, Kenneth R Hess, Mahul B Amin, et al.
Pageof 122